方盛製藥(603998.SH):湖南珂信以3.57億元向盈康生命出售其下屬醫院長沙珂信51%的股權
格隆匯4月7日丨方盛製藥(603998.SH)公佈,2025年4月7日,同系方盛函告公司,湖南珂信已於日前召開股東會,決定以3.57億元向盈康生命出售其下屬醫院長沙珂信51%的股權,且後續將根據業績承諾目標的完成情況,分別轉讓長沙珂信29%、20%的股權;湖南珂信擬通過回購股權的方式將其出售長沙珂信股權獲得的股權轉讓款按照其股東會決議的安排向相關股東回購股權,並對其部分非現金資產進行分配。回購股權款將根據湖南珂信與盈康生命交易長沙珂信的股權節奏分三期進行付款,按照同系方盛持有的湖南珂信26.0018%股權(含轉讓予陳歷宏先生或其指定關聯方尚未支付股權轉讓價款的16.30%股權)計算,預計將獲得回購款15,468.34萬元;如湖南珂信完成轉讓長沙珂信51%的股權,則對應湖南珂信將支付至同系方盛的第一期回購款爲8,760.55萬元。
截至本公告披露日,公司對同系方盛的實繳出資尚有9,850萬元未收回,同系方盛函告已確認在收到湖南珂信股權回購分期款及陳歷宏先生或其指定關聯方償還的股權轉讓款後,將同步支付公司的實繳出資款,預計收到第一期回購款至多可收回8,760.55萬元(不考慮同系方盛扣除相關日常運營費用),佔公司未收回實繳出資金額的88.94%。同系方盛收回股權轉讓款及股權回購款後,預計所獲得資金能夠支付公司未收回的全部實繳出資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.